Recent evidence showed that high expression of IFITM1 was associated with therapeutically resistant and aggressive disease courses for lung, esophageal and colon cancer, while a protective role was reported in cervical cancer and gastric cancer20–23. This evidence concerns the gene IFITM1 and colonic neoplasm.